Stepped care medical treatment for cirrhotic ascites: analysis of factors influencing the response to treatment.
Thirty-two patients with liver cirrhosis and ascites were treated by stepped care diuretic treatment as follows: step 1, placed on a 35 mEq sodium diet; step 2, given 400 mg/day of potassium canrenoate in addition to step 1 treatment; step 3, given 40-80 mg/day of furosemide in addition to step 2 treatment. Eleven out of 32 patients (34.4%, group 1) and 12 of 21 patients (57.1%, group 2) lost their ascites at step 1 and step 2, respectively. The remaining nine patients (group 3) required step 3 treatment. Basal urinary sodium excretion and creatinine clearance were significantly lower and beta 2-microglobulin was significantly higher in group 3 than those in groups 1 and 2. Elevation of basal plasma renin activity and norepinephrine was evident only in group 3. In group 1, urinary sodium excretion decreased after the treatment. In group 2, plasma alpha-atrial natriuretic polypeptide was lowered and plasma renin activity and norepinephrine were elevated after the treatment. These results suggest that basal renal function and plasma renin activity and norepinephrine levels are useful indices to predict the effect of ascites treatment and that responders to sodium restriction or potassium canrenoate may be in the state of vascular overflow, while non-responders to potassium canrenoate may be in the state of vascular underfilling. In summary, this stepped care treatment is safe without any side effects, although the diuretics themselves may lead to relative vascular underfilling.
Takaya
A
A
Third Department of Internal Medicine, Nara Medical University, Kashihara, Japan.
Fukui
H
H
Matsumura
M
M
Uemura
M
M
Kojima
H
H
Okamoto
S
S
Tsujii
T
T
D000368:Aged; D001201:Ascites / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D001835:Body Weight; D002191:Canrenoic Acid / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood / Q000652:urine; D004359:Drug Therapy, Combination; D005260:Female; D005665:Furosemide / Q000627:therapeutic use*; D006728:Hormones / Q000097:blood; D006801:Humans; D008103:Liver Cirrhosis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011188:Potassium / Q000097:blood / Q000652:urine; D012083:Renin / Q000097:blood; D012964:Sodium / Q000097:blood / Q000652:urine; D012982:Sodium, Dietary / Q000627:therapeutic use*
D006728:Hormones; D012982:Sodium, Dietary; D005665:Furosemide; D002191:Canrenoic Acid; D012964:Sodium; D003404:Creatinine; D012083:Renin; D011188:Potassium